The Complete Guide to GLP-1 Receptor Agonist Peptides

NorthPeptide Research Team  |  April 10, 2026

What Is GLP-1?

Glucagon-like peptide-1 (GLP-1) is a 30–31 amino acid incretin hormone secreted by intestinal L-cells in response to nutrient ingestion, particularly glucose and fat. It is derived by post-translational processing of proglucagon and circulates in two biologically active forms: GLP-1(7-36)NH₂ (predominant in humans) and GLP-1(7-37). Both forms bind and activate the GLP-1 receptor (GLP-1R) with equivalent potency.

Native GLP-1 has a plasma half-life of only approximately 2 minutes, rapidly inactivated by the ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4) and cleared by the kidneys. This ultra-short half-life makes native GLP-1 impractical as a therapeutic — it was the drive to overcome this limitation that produced the generation of GLP-1 receptor agonists that has become one of the most transformative pharmaceutical classes of the 21st century.

The GLP-1 Receptor and Its Signaling

The GLP-1 receptor is a class B G protein-coupled receptor (GPCR) expressed in multiple tissues — pancreas, intestine, brain, heart, kidney, and lung — reflecting GLP-1’s broad physiological role beyond simple glucose control.

Upon GLP-1R activation, the receptor couples primarily to G_s, activating adenylyl cyclase and raising intracellular cAMP. PKA-mediated downstream signaling drives glucose-dependent insulin secretion from beta cells. At supraphysiological cAMP concentrations, additional second messenger pathways (Epac2, PI3K, ERK) become engaged. The tissue-specific expression pattern of GLP-1R explains why GLP-1 RAs produce a constellation of effects spanning multiple organ systems.

GLP-1 Actions by Target Organ

The glucose-dependence of GLP-1-mediated insulin secretion is pharmacologically critical: GLP-1 RAs enhance insulin release only when blood glucose is elevated, which dramatically reduces hypoglycemia risk compared to agents that stimulate insulin regardless of glycemia.

How GLP-1 Receptor Agonists Work

GLP-1 RAs are synthetic peptides or small molecules that bind GLP-1R with high affinity and activate the same signaling cascades as native GLP-1 — but with engineered pharmacokinetics that extend duration of action from minutes to days or weeks. The structural strategies employed include:

• DPP-4 resistance — Substitution of the DPP-4 cleavage site (position 8 Ala → Aib or Pro)
• Albumin binding — Fatty acid chain attachment enabling reversible albumin binding, slowing renal clearance
• Structural modifications — Additional amino acid substitutions that slow proteolytic degradation
• Absorption enhancers — For oral formulations (SNAC technology used in oral semaglutide)

Major GLP-1 Receptor Agonist Peptides

Semaglutide (GLP-1 agonist)

Semaglutide is a 31-amino-acid GLP-1 analog developed by Novo Nordisk. Three structural modifications enable its once-weekly dosing: DPP-4 resistance via Aib at position 8, a C18 fatty acid chain at position 26 for albumin binding (half-life ~7 days), and Arg at position 34. Semaglutide is approved as Ozempic (T2D), Wegovy (weight management, 2.4 mg weekly), and Rybelsus (oral T2D).

Key clinical data:

• STEP 1 trial: 14.9% mean weight reduction at 68 weeks (vs. 2.4% placebo); one-third of participants lost ≥20% body weight (PMID: 33567185).
• STEP 5 (2-year): 15.2% sustained weight loss with continued treatment.
• SUSTAIN 6 (cardiovascular): 26% reduction in MACE vs. placebo (HR 0.74) in T2D patients (PMID: 27633186).
• SELECT trial (2023): 20% MACE reduction in non-diabetic adults with obesity and established CVD — the first demonstration of cardiovascular benefit of a weight management agent independent of diabetes treatment.
• FLOW trial (kidney): Stopped early for efficacy; semaglutide significantly reduced CKD progression.

Tirzepatide (GLP-1 + GIP dual agonist)

Tirzepatide, developed by Eli Lilly (Mounjaro for T2D, Zepbound for obesity), is a 39-amino-acid peptide that is the first approved dual GIP and GLP-1 receptor co-agonist. Its GLP-1 activity is approximately equivalent to semaglutide, but the addition of glucose-dependent insulinotropic polypeptide (GIP) receptor agonism provides complementary metabolic effects — enhanced insulin secretion, adipose tissue metabolism, and potentially central appetite regulation through GIP receptors in the CNS. Half-life: approximately 5 days.

Key clinical data:

• SURMOUNT-1: 20.9% mean weight reduction at 72 weeks with 15 mg tirzepatide — superior to semaglutide 2.4 mg in indirect comparisons (PMID: 35658024).
• SURPASS-2: Tirzepatide 15 mg superior to semaglutide 1 mg for HbA1c reduction and weight loss in direct head-to-head T2D trial.

View Tirzepatide Research Peptide →

Retatrutide (GLP-1 + GIP + Glucagon triple agonist)

Retatrutide (LY3437943), developed by Eli Lilly, is the most potent weight loss agent to emerge from clinical trials to date. It adds glucagon receptor (GCGR) agonism to the GLP-1 and GIP receptor engagement of tirzepatide, creating a true triagonist. Glucagon activation increases hepatic glucose output (generally considered undesirable in isolation) but at the GLP-1-balanced ratios in retatrutide, this is more than offset by enhanced energy expenditure, increased lipolysis, and improved fatty acid oxidation. Half-life: approximately 6 days.

Key clinical data:

• Phase 2 trial (PMID: 37385677): Mean weight loss of 24.2% at 48 weeks with highest dose — with 100% of participants losing ≥5% body weight at that dose (PMID: 37385677). This is the highest weight loss reported in any peptide clinical trial to date.
• Phase 3 TRIUMPH program is ongoing.

View Retatrutide Research Peptide →

Cagrilintide (Amylin analog in combination with semaglutide)

Cagrilintide is not a GLP-1 agonist itself — it is a long-acting amylin analog developed by Novo Nordisk. Amylin (islet amyloid polypeptide, IAPP) is co-secreted with insulin from beta cells and acts on amylin receptors in the brainstem to enhance satiety. Cagrilintide achieves a half-life of approximately 7 days through fatty acid chain modification. Its clinical interest lies primarily in the combination program CagriSema (cagrilintide + semaglutide), which targets two distinct satiety pathways simultaneously.

Key data: Phase 2 CagriSema data showed 15.6% weight reduction at 32 weeks — comparable to semaglutide alone in early-stage data. Phase 3 REDEFINE trials are evaluating higher-dose CagriSema combinations with anticipated results suggesting enhanced efficacy over semaglutide monotherapy.

Survodutide (GLP-1 + Glucagon dual agonist)

Survodutide, developed by Boehringer Ingelheim and Zealand Pharma, is a dual GLP-1/glucagon receptor agonist (no GIP component). The glucagon agonism component enhances energy expenditure and fatty acid oxidation in a manner analogous to retatrutide, while GLP-1 receptor activation provides appetite suppression and insulin sensitization. Half-life: approximately 7 days.

Key data: Survodutide has shown particular promise in MASH (metabolic dysfunction-associated steatohepatitis) research — a phase 2 trial reported histological resolution of MASH in a significantly higher proportion of treated patients vs. placebo, positioning survodutide as a potential MASH therapeutic alongside its obesity applications. Phase 3 obesity and MASH trials are ongoing.

Mazdutide (GLP-1 + Glucagon dual agonist)

Mazdutide (IBI362), developed by Innovent Biologics, is another GLP-1/glucagon dual receptor agonist primarily in clinical development in China, where it has progressed through Phase 3 trials for T2D and obesity. Its dual mechanism parallels survodutide — GLP-1 for appetite/glucose control, glucagon for energy expenditure enhancement. Phase 2 data reported approximately 10% weight reduction at 24 weeks with 4 mg weekly dosing in Chinese adults with obesity.

Comprehensive Comparison Table

Mechanism of Weight Loss: Beyond Appetite

The magnitude of weight loss achieved by GLP-1 RAs — particularly the multi-agonist generation — reflects mechanisms that extend well beyond simple appetite suppression:

1. Hypothalamic Appetite Circuit Modulation

GLP-1 activates GLP-1R in the arcuate nucleus, stimulating anorexigenic POMC/CART neurons and inhibiting orexigenic NPY/AgRP neurons. This shifts the homeostatic balance toward reduced hunger and earlier satiety.

2. Reward Pathway Desensitization

Neuroimaging studies in semaglutide-treated subjects demonstrate reduced activation of mesolimbic reward centers in response to food cues. GLP-1R on dopaminergic neurons in the ventral tegmental area and nucleus accumbens modulates the hedonic (pleasure-driven) component of eating — reducing cravings and food-seeking behavior independent of homeostatic hunger.

3. Gastric Emptying Delay

Slowed gastric emptying reduces the rate of nutrient absorption, blunting postprandial glucose excursions and prolonging the sensation of fullness after meals. This effect is most pronounced early in treatment and partially attenuates with chronic dosing.

4. GIP-Mediated Adipose Effects (tirzepatide, retatrutide)

GIP receptors are highly expressed on adipocytes. GIP receptor agonism in the context of co-administered GLP-1 appears to enhance lipolysis in adipose tissue and reduce adipogenesis, contributing to the fat-specific weight loss advantage of dual/triple agonists over pure GLP-1 agents.

5. Glucagon-Enhanced Energy Expenditure (retatrutide, survodutide, mazdutide)

Glucagon receptor agonism increases hepatic glucose output (balanced and mitigated by the GLP-1 component), enhances fatty acid oxidation, and drives thermogenic brown adipose tissue activation. This energy expenditure component likely explains why triple-agonist retatrutide outperforms dual-agonist tirzepatide in weight loss despite similar receptor engagement strategies.

Metabolic Benefits Beyond Weight Loss

Cardiovascular Protection

GLP-1 RAs have consistently demonstrated cardiovascular protection in large outcomes trials. The SELECT trial (semaglutide 2.4 mg) showed 20% MACE reduction in non-diabetic subjects with obesity — establishing cardiometabolic protection as a class effect (PMID: 37952383). Mechanisms include reduced inflammation, improved endothelial function, direct cardiomyocyte GLP-1R signaling, and weight-loss-mediated reduction in cardiac load.

Kidney Protection

The FLOW trial demonstrated that semaglutide significantly reduced CKD progression and renal-related death in patients with T2D and CKD. GLP-1R in renal tubular cells mediates anti-inflammatory and natriuretic effects that appear to slow CKD progression independently of blood pressure and glucose changes.

Liver Disease (MASH)

Multiple GLP-1 RAs have demonstrated histological improvement in MASH. Semaglutide phase 2 data showed steatohepatitis resolution in 59% of patients vs. 17% placebo. Survodutide, with its glucagon receptor component enhancing hepatic fat oxidation, may offer particular advantages in MASH and is in Phase 3 liver-specific trials.

Neurological and Addiction Research

GLP-1R is expressed throughout the central nervous system. Preclinical and early clinical data suggest GLP-1 RAs reduce alcohol and substance use through dopaminergic pathway modulation — clinical trials for alcohol use disorder with semaglutide are ongoing. GLP-1 agonism has also shown neuroprotective signals in Parkinson’s and Alzheimer’s disease preclinical models, with clinical trials in neurodegeneration underway.

Side Effect Class Overview

The Reclassification Context (2026)

The regulatory environment for peptide research compounds has evolved significantly in 2026 following the RFK Jr.-era FDA review and associated reclassification discussions. Certain peptides have been reclassified under Category II or Category III, affecting compounding pharmacy access and research supply chains. Researchers should remain current on the applicable regulatory framework for their jurisdiction.

For context on the peptide reclassification landscape: RFK Peptide Category 2 Reclassification Update

Future Directions

The GLP-1 agonist research landscape as of 2026 is advancing on several fronts:

• Oral formulations — Higher-dose oral semaglutide (25 mg, 50 mg) is in late-stage development for weight management; oral tirzepatide programs are also underway
• Combination strategies — CagriSema, GLP-1 + amylin combos, and co-formulations with insulin are extending the weight loss ceiling
• Muscle preservation — Combination of GLP-1 RAs with myostatin inhibitors or anabolic peptides is an active research area to address lean mass loss
• CNS indications — Alzheimer’s, Parkinson’s, addiction, and depression trials are expanding the indication landscape
• MASH therapeutics — Survodutide and semaglutide are leading candidates for what may become a major new indication
• Bispecific targeting — Next-generation molecules targeting GLP-1R plus FGF21R, Y2R, or other metabolic regulators are in early development

Research Peptides in the GLP-1 Space

For researchers studying incretin and metabolic signaling pathways, NorthPeptide’s catalog includes:

Retatrutide
Tirzepatide
Cagrilintide
Survodutide
Mazdutide

References

1. Wilding JPH et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).” N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
2. Marso SP et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6).” N Engl J Med. 2016;375:1834-1844. PMID: 27633186
3. Lincoff AM et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).” N Engl J Med. 2023;389:2221-2232. PMID: 37952383
4. Jastreboff AM et al. “Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).” N Engl J Med. 2022;387(3):205-216. PMID: 35658024
5. Jastreboff AM et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023;389:514-526. PMID: 37385677
6. Drucker DJ. “The biology of incretin hormones.” Cell Metab. 2006;3(3):153-65. PMID: 16517403
7. Knudsen LB, Lau J. “The Discovery and Development of Liraglutide and Semaglutide.” Front Endocrinol. 2019;10:155. PMID: 30915044